Australia markets closed

Biocartis Group NV (BCART.BR)

Brussels - Brussels Delayed price. Currency in EUR
Add to watchlist
3.0100+0.1600 (+5.61%)
At close: 05:35PM CET
Full screen
Previous close2.8500
Open2.9150
Bid0.0000 x 0
Ask0.0000 x 0
Day's range2.9150 - 3.1450
52-week range2.8150 - 4.9000
Volume246,751
Avg. volume63,399
Market cap173.213M
Beta (5Y monthly)1.67
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • GlobeNewswire

    Press release Biocartis Group NV: Large UK Study Shows Rapid EGFR Testing with Idylla™ Alongside NGS Has Potential to Enhance Lung Cancer Patient Health Outcomes

    PRESS RELEASE: 25 January 2022, 07:00 CET Large UK Study Shows Rapid EGFR Testing with Idylla™ Alongside NGS Has Potential to Enhance Lung Cancer Patient Health Outcomes Lung cancer accounts for the largest number of cancer deaths worldwide102 Idylla™ EGFR Mutation Test (CE-IVD) results of lung adenocarcinoma patients1 were compared with NGS 6 percent of the patients died before the NGS report was available; of the 17 patients whose condition deteriorated rapidly, 3 (18 percent) were identified

  • GlobeNewswire

    Press release Biocartis Group NV: BIOCARTIS MEETS 2021 KEY OBJECTIVES

    PRESS RELEASE: REGULATED INFORMATION10 January 2022, 07:00 CET BIOCARTIS MEETS 2021 KEY OBJECTIVES Mechelen, Belgium, 10 January 2022 - Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), announced the Company has achieved its 2021 key business objectives which were focused on three performance indicators: expanded installed base of its rapid and easy-to-use Idylla™ molecular diagnostics platform, increased Idylla™ commercial

  • GlobeNewswire

    Press release Biocartis Group NV: Biocartis’ Idylla™ SARS-CoV-2 testing Successfully Detects Omicron Variant

    PRESS RELEASE: 9 December 2021, 07:00 CET Biocartis’ Idylla™ SARS-CoV-2 testing Successfully Detects Omicron Variant Mechelen, Belgium, 9 December 2021 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that the Company performed an in-silico analysis which concluded that the Idylla™ SARS-CoV-2 Test (CE-IVD) and the Idylla™ SARS-CoV-2/Flu/RSV1 Panel (CE-IVD) detect the currently available B.1.1.529/Omicron